A randomized, blinded, phase 2 study of letrozole plus the farnesyl transferase inhibitor Zarnestra (R115777) [tipifarnib] and letrozole plus placebo in the treatment of advanced breast cancer after antiestrogen therapy.

Trial Profile

A randomized, blinded, phase 2 study of letrozole plus the farnesyl transferase inhibitor Zarnestra (R115777) [tipifarnib] and letrozole plus placebo in the treatment of advanced breast cancer after antiestrogen therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2013

At a glance

  • Drugs Tipifarnib (Primary) ; Letrozole
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Feb 2012 Actual patient number changed from 120 to 121 as reported by ClinicalTrials.gov.(NCT00050141)
    • 21 Feb 2012 Actual patient number changed from 120 to 121 as reported by ClinicalTrials.gov.(NCT00050141)
    • 21 Feb 2012 Actual patient number changed from 120 to 121 as reported by ClinicalTrials.gov.(NCT00050141)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top